Glucagon‐like peptide‐2 inhibits antral emptying in man, but is not as potent as glucagon‐like peptide‐1

References

• Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983;302 (5910):716–8.
   Google Scholar
• Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature 1983;304;(5924):368–71.
   PubMed Web of Science ®Google Scholar
• Holst JJ. Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 1999;10:229–35.
   PubMed Web of Science ®Google Scholar
• Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ, Truncated. GLP-1 (proglucagon 78107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38: 665–73.
   Google Scholar
• Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515–20.
   PubMed Web of Science ®Google Scholar
• Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999;44:81–6.
   PubMed Web of Science ®Google Scholar
• Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, et al. A meta-analysis of the effect of glucagonlike peptide-1 (7–36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001;86:4382–9.
   PubMed Web of Science ®Google Scholar
• Holst JJ, Orskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987;211:169–74.
   PubMed Web of Science ®Google Scholar
• Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagonlike peptide-1 (proglucagon-(78–107) amide) on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988;123: 2009–13.
   Google Scholar
• Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulindependent) diabetic patients. Diabetologia 1993;36:741–4.
   PubMed Web of Science ®Google Scholar
• Gleeson Mh, Bloom SR, Polak JM, Henry K, Dowling RH. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut 1971;12:773–82.
   Google Scholar
• Stevens FM, Flanagan RW, O’Gorman D, Buchanan KD. Glucagonoma syndrome demonstrating giant duodenal villi. Gut 1984;25:784–91.
   Google Scholar
• Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996;93:7911–6.
   PubMed Web of Science ®Google Scholar
• Lovshin J, Drucker DJ. New frontiers in the biology of GLP-2. Regul Pept 2000;90:27–32.
   PubMedGoogle Scholar
• Wojdemann M, Wettergren A, Hartmann B, Hilsted L, Holst JJ. Inhibition of sham feeding—stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 1999;84: 2513–7.
   Google Scholar
• Wojdemann M, Wettergren A, Hartmann B, Holst JJ. Glucagonlike peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998;33:828–32.
   PubMed Web of Science ®Google Scholar
• Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986;119:1467–75.
   PubMed Web of Science ®Google Scholar
• Hartmann B, Johnsen AH, Orskov C, Adelhorst K, Thim L, Holst JJ. Structure, measurement, and secretion of human glucagonlike peptide-2. Peptides 2000;21:73–80.
   PubMed Web of Science ®Google Scholar
• Hartmann B, Holst JJ, Orskov C. Structure, analysis and secretion of human glucagon-like peptide-2 (GLP-2). Diabetes 2000;Suppl 2.
   Google Scholar
• Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 1996;31: 665–70.
   Google Scholar
• Raben A, Tagliabue A, Astrup A. The reproducibility of subjective appetite scores. [published erratum appears in Br J Nutr 1995;74:283]. Br J Nutr 1995;73: 517–30.
   Google Scholar
• Pedersen JF. A modified sonographic technique for assessment of gastric emptying of liquid. Acta Radiol 2003;44:340–2.
   PubMed Web of Science ®Google Scholar
• Hveem K, Jones KL, Chatterton BE, Horowitz M. Scintigraphic measurement of gastric emptying and ultrasonographic assessment of antral area: relation to appetite. Gut 1996;38:816–21.
   PubMed Web of Science ®Google Scholar
• Ricci R, Bontempo I, Corazziari E, La Bella A, Torsoli A. Real time ultrasonography of the gastric antrum. Gut 1993;34:173–6.
   Google Scholar
• Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994;43:535–9.
   Google Scholar
• Orskov C, Holst JJ, Poulsen SS, Kirkegaard P. Pancreatic and intestinal processing of proglucagon in man. Diabetologia 1987;30:874–81.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997;273:E981–8.
   PubMed Web of Science ®Google Scholar
• Bloom SR. Gut hormones in adaptation. Gut 1987; 28 Suppl: 31–5.
   Google Scholar
• Holst JJ. Enteroglucagon. Annu Rev Physiol 1997;59:257–71.
   PubMed Web of Science ®Google Scholar
• Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80: 952–7.
   Google Scholar
• Larsen PJ, Tang-Christensen M, Knudsen LB. Systemic administration of the long-acting GLP-1 derivative NN 2211 induces lasting and reversible loss of body adiposity. Diabetes 2000;48 Suppl 1:A60.
   Google Scholar
• Wettergren A, Wojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998;275:G984–G92.
   Google Scholar
• Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997;273:G920–G7.
   Google Scholar
• Nishizawa M, Nakabayashi H, Kawai K, Ito T, Kawakami S, Nakagawa A, et al. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J AutonNerv Syst 2000;80:14–21.
   PubMed Web of Science ®Google Scholar
• Fung LC, Chisholm C, Greenberg GR. Glucagon-like peptide-1-(7–36) amide and peptide YY mediate intraduodenal fat-induced inhibition of acid secretion in dogs. Endocrinology 1998;139: 189–94.
   Google Scholar
• Burks TF, Galligan JJ, Porreca F, Barber WD. Regulation of gastric emptying. Fed Proc 1985;44:2897–901.
   PubMedGoogle Scholar
• Debas HT, Farooq O, Grossman MI. Inhibition of gastric emptying is a physiological action of cholecystokinin. Gastroenterology 1975;68:1211–7.
   Google Scholar
• Higham A, Vaillant C, Yegen B, Thompson DG, Dockray GJ. Relation between cholecystokinin and antral innervation in the control of gastric emptying in the rat. Gut 1997;41:24–32.
   Google Scholar
• Houpt KA. Gastrointestinal factors in hunger and satiety. Neurosci Biobehav Rev 1982;6:145–64.
   PubMed Web of Science ®Google Scholar
• Schmidt PT, Naslund E, Gryback P, Jacobsson H, Hartman B, et al. Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept 2003;116:21–5.
   PubMed Web of Science ®Google Scholar